Review





Similar Products

94
R&D Systems e selectin
E Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e selectin/product/R&D Systems
Average 94 stars, based on 1 article reviews
e selectin - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
R&D Systems mouse anti human p selectin
Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial <t>cells.</t> <t>P-selectin</t> (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="250" height="auto" />
Mouse Anti Human P Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human p selectin/product/R&D Systems
Average 94 stars, based on 1 article reviews
mouse anti human p selectin - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Novus Biologicals e selectin novus biologicals
Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial <t>cells.</t> <t>P-selectin</t> (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="250" height="auto" />
E Selectin Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e selectin novus biologicals/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
e selectin novus biologicals - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Novus Biologicals p selectin novus biologicals
Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial <t>cells.</t> <t>P-selectin</t> (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="250" height="auto" />
P Selectin Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p selectin novus biologicals/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
p selectin novus biologicals - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
R&D Systems anti human p selectin
( A – C <t>):</t> <t>P-selectin</t> expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.
Anti Human P Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human p selectin/product/R&D Systems
Average 94 stars, based on 1 article reviews
anti human p selectin - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
R&D Systems human il 20 elisa kit
ROC curve of <t>serum</t> <t>IL-20</t> (A) , serum Apelin-13 (B) , aqueous humor IL-20 (C) , and aqueous humor Apelin-13 (D) levels for predicting poor efficacy of phacoemulsification combined with IOL implantation surgery in cataract patients.
Human Il 20 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il 20 elisa kit/product/R&D Systems
Average 94 stars, based on 1 article reviews
human il 20 elisa kit - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
R&D Systems cd62 e p
EV surface marker changes after RIC treatment: The expression of the EV-markers <t>CD62</t> and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints
Cd62 E P, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd62 e p/product/R&D Systems
Average 94 stars, based on 1 article reviews
cd62 e p - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
R&D Systems bba1
EV surface marker changes after RIC treatment: The expression of the EV-markers <t>CD62</t> and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints
Bba1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bba1/product/R&D Systems
Average 94 stars, based on 1 article reviews
bba1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
R&D Systems sn4 c3 3a2 cd62 e p r d systems bba1
EV surface marker changes after RIC treatment: The expression of the EV-markers <t>CD62</t> and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints
Sn4 C3 3a2 Cd62 E P R D Systems Bba1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sn4 c3 3a2 cd62 e p r d systems bba1/product/R&D Systems
Average 94 stars, based on 1 article reviews
sn4 c3 3a2 cd62 e p r d systems bba1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=Figure 6C . Scale bar: 100 µm. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis

doi: 10.3389/fimmu.2026.1749811

Figure Lengend Snippet: Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to Figure 6C . Scale bar: 100 µm.

Article Snippet: Cells were washed again and treated with the following specific antibodies: FITC-conjugated rabbit anti-human C3c-complement (Dako, that recognizes C3c, part of C3 and C3b, 1:300 final dilution in Dapi 1 μg/mL); or rabbit anti-human complement C5b-9 complex (Calbiochem, 1:200 final dilution in PBS1X) followed by FITC-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi); or goat anti-human C4 (Abcam, 1:100 final dilution in PBS1X) followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:200 final dilution in Dapi 1 μg/mL); or FITC-conjugated anti-human IgG (Sigma Aldrich, 1:32 final dilution in 1 μg/mL Dapi); or mouse anti-human P-selectin (R&D System, 20 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:60 final dilution in 1 μg/mL Dapi); or rabbit anti-human vWF (Dako, 10 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi).

Techniques: Expressing, Control, Staining, Confocal Microscopy

( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

Journal: Pathogens

Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

doi: 10.3390/pathogens15020196

Figure Lengend Snippet: ( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

Techniques: Expressing

( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

Journal: Pathogens

Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

doi: 10.3390/pathogens15020196

Figure Lengend Snippet: ( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

Techniques: Clinical Proteomics

ROC curve of serum IL-20 (A) , serum Apelin-13 (B) , aqueous humor IL-20 (C) , and aqueous humor Apelin-13 (D) levels for predicting poor efficacy of phacoemulsification combined with IOL implantation surgery in cataract patients.

Journal: Frontiers in Medicine

Article Title: Efficacy evaluation and predictive value of IL-20 and Apelin-13 after cataract surgery by phacoemulsification combined with IOL implantation

doi: 10.3389/fmed.2025.1737194

Figure Lengend Snippet: ROC curve of serum IL-20 (A) , serum Apelin-13 (B) , aqueous humor IL-20 (C) , and aqueous humor Apelin-13 (D) levels for predicting poor efficacy of phacoemulsification combined with IOL implantation surgery in cataract patients.

Article Snippet: The human IL-20 ELISA kit (R&D Systems, USA; Catalog # DY724) from lot # 2365891 (expiry: 03/2025) and the human Apelin-13 ELISA kit (Phoenix Pharmaceuticals, USA; Catalog # EK-057-23) from lot # PHX1022 (expiry: 02/2025) were used.

Techniques:

ROC curve of serum IL-20/Apelin-13 ratio (A) and aqueous humor IL-20/Apelin-13 ratio (B) for predicting poor efficacy of phacoemulsification combined with IOL implantation surgery in cataract patients.

Journal: Frontiers in Medicine

Article Title: Efficacy evaluation and predictive value of IL-20 and Apelin-13 after cataract surgery by phacoemulsification combined with IOL implantation

doi: 10.3389/fmed.2025.1737194

Figure Lengend Snippet: ROC curve of serum IL-20/Apelin-13 ratio (A) and aqueous humor IL-20/Apelin-13 ratio (B) for predicting poor efficacy of phacoemulsification combined with IOL implantation surgery in cataract patients.

Article Snippet: The human IL-20 ELISA kit (R&D Systems, USA; Catalog # DY724) from lot # 2365891 (expiry: 03/2025) and the human Apelin-13 ELISA kit (Phoenix Pharmaceuticals, USA; Catalog # EK-057-23) from lot # PHX1022 (expiry: 02/2025) were used.

Techniques:

EV surface marker changes after RIC treatment: The expression of the EV-markers CD62 and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints

Journal: BMC Neuroscience

Article Title: Exploring extracellular vesicle surface markers and microRNA regulation following remote ischemic conditioning in patients with stroke; a randomized-controlled pilot study

doi: 10.1186/s12868-025-00993-1

Figure Lengend Snippet: EV surface marker changes after RIC treatment: The expression of the EV-markers CD62 and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints

Article Snippet: CD62 E/P , R & D Systems , BBA1 , BBIG-E(13D5).

Techniques: Marker, Expressing

Correlation analysis of significant miRNA measurements (hsa-miR-19b-3p, hsa-miR-30d-5p, hsa-miR-374a-5p, hsa-miR-20a/20b-5p, hsa-miR-24-3p) and CD62/P-selectin. The histograms on the diagonal show the distribution of each variable. The lower triangular panels depict scatter plots with fitted lines, illustrating the linear relationships between pairs of variables. The upper triangular panels display the correlation coefficients, with significance levels indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001)

Journal: BMC Neuroscience

Article Title: Exploring extracellular vesicle surface markers and microRNA regulation following remote ischemic conditioning in patients with stroke; a randomized-controlled pilot study

doi: 10.1186/s12868-025-00993-1

Figure Lengend Snippet: Correlation analysis of significant miRNA measurements (hsa-miR-19b-3p, hsa-miR-30d-5p, hsa-miR-374a-5p, hsa-miR-20a/20b-5p, hsa-miR-24-3p) and CD62/P-selectin. The histograms on the diagonal show the distribution of each variable. The lower triangular panels depict scatter plots with fitted lines, illustrating the linear relationships between pairs of variables. The upper triangular panels display the correlation coefficients, with significance levels indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001)

Article Snippet: CD62 E/P , R & D Systems , BBA1 , BBIG-E(13D5).

Techniques: